A single-center, self-controlled, phase I clinical trial of mitoxantrone hydrochloride injection for lymph tracing for sentinel lymph node identification of breast cancer

作者
Benlong Yang,Shuyue Zheng,Xiaoyan Huang,Jiajian Chen,Zhebin Liu,Guangyu Liu,Shujun Wang,Zhimin Shao,Jiong Wu
出处
期刊:Gland surgery [AME Publishing Company]
卷期号:10 (3): 992-1001 被引量:14
标识
DOI:10.21037/gs-20-694
摘要

BACKGROUND: Mitoxantrone hydrochloride injection for lymph tracing (MHI) is a novel lymphatic tracer for sentinel lymph node (SLN) in patients with early breast cancer but exhibited remarkable liver, kidney, and hematologic toxicities in previous studies. Here, the pharmacokinetics and pharmacodynamics profiles of MHI were evaluated to surmise safety and tolerability. METHODS: Phase 1 open-label, single center, and dose escalation study was performed. Ten patients with invasive breast cancer received 0.5, 1.0, or 2.0 mL of MHI into the breast tissues surrounding the tumor for lymphatic mapping. All of these patients were injected with 2 mCi nuclide-labeled sulfur colloid as a self-control 24 to 48 hours before surgery. Safety was assessed by the incidence of adverse events graded by the National Cancer Institute Common Terminology Criteria, version 4.0.3 (CTCAE4.0.3). Blood samples for pharmacokinetic analyses were collected before and after administration at 15, 30, 60, 120, and 240 min of the injection of MHI. RESULTS: Up to the cutoff date of the study (Aug 8, 2018), no dose-limiting toxic effects or obvious allergic reactions were observed. Only one case of an adverse event was certainly related to MHI, where it caused blue discoloration of the local skin over the injection site after the operation, but this stain gradually went away. The peak level of MHI was achieved after 15-30 min post injection and completely eliminated from the plasma after 60 min. There were no significant differences in the number of lymph nodes detected by MHI and radioactive colloid. Only one patient with lymph node macrometastases had no SLN detected by either the radioactive colloid or the MHI. CONCLUSIONS: At a dose of up to 2.0 mL, MHI was well tolerated and safe for conducting SLN biopsies in patients with breast cancer. Although there was a case with blue discoloration of the local skin over the injection site after the operation, and remained for a short period of time, but the overall safety was acceptable. Here, we approached a novel SLN tracing slant; however, more investigations of MHI should be performed for further evaluations. (Chinadrugtrials.org.cn number: CXHL1301201, Date of registration: October 12, 2015.).

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
丘比特的应助被科研通管家采纳,获得10
刚刚
刚刚
科研通AI6.3的应助被Yaon-Xu采纳,获得30
刚刚
xigu发布了新的文献求助10
刚刚
syvshc的应助被科研通管家采纳,获得10
1秒前
上官若男的应助被科研通管家采纳,获得10
1秒前
秋风的应助被科研通管家采纳,获得20
1秒前
科目三的应助被科研通管家采纳,获得10
1秒前
1秒前
DW的应助被科研通管家采纳,获得10
1秒前
1秒前
lcy发布了新的文献求助10
1秒前
无极微光的应助被科研通管家采纳,获得20
2秒前
2秒前
桌子完成签到,获得积分10
2秒前
小马甲的应助被科研通管家采纳,获得10
2秒前
彭于晏的应助被科研通管家采纳,获得10
2秒前
怀石逾沙发布了新的文献求助10
2秒前
orixero的应助被科研通管家采纳,获得10
3秒前
zhangchaobo发布了新的文献求助10
3秒前
桃桃发布了新的文献求助10
3秒前
molihuakai的应助被科研通管家采纳,获得10
3秒前
Cakoibao的应助被科研通管家采纳,获得10
3秒前
今后的应助被科研通管家采纳,获得10
3秒前
Cakoibao的应助被科研通管家采纳,获得10
3秒前
3秒前
领导范儿的应助被科研通管家采纳,获得10
3秒前
ding的应助被科研通管家采纳,获得10
3秒前
Orange的应助被科研通管家采纳,获得10
4秒前
深情安青的应助被科研通管家采纳,获得10
4秒前
4秒前
4秒前
火土发布了新的文献求助10
4秒前
4秒前
Cakoibao的应助被科研通管家采纳,获得10
4秒前
七只鱼完成签到,获得积分10
4秒前
打打的应助被科研通管家采纳,获得10
4秒前
科研通AI6.2的应助被Yaon-Xu采纳,获得10
4秒前
活A完成签到,获得积分10
4秒前
FashionBoy的应助被科研通管家采纳,获得10
4秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180586
求助须知:如何正确求助?哪些是违规求助? 9570581
关于积分的说明 21813457
捐赠科研通 7776777
什么是DOI,文献DOI怎么找? 3433294
关于科研通互助平台的介绍 2557547
邀请新用户注册赠送积分活动 2479253